513 - Cefiderocol Retains in vitro Activity Against Enterobacterales Non-Susceptible to β-lactam-β-lactamase Inhibitor Combinations

Saturday, October 19, 2024

11:18 AM – 11:30 AM US PT

Location: 403 A

Presenting Author(s)

Boudewijn L. DeJonge, PhD (he/him/his)

Director Microbiology
Shionogi Inc.
Florham Park, New Jersey, United States

Slides

Co-Author(s)

Sean T. Nguyen, PharmD

Director, Medical Affairs
Shionogi Inc.
Florham Park, New Jersey, United States
Jason J. Bryowsky, PharmD, MS

Director, Field Microbiology
Shionogi Inc.
Florham Park, New Jersey, United States
JM

Joshua Maher, PhD

Research Scientist
JMI Laboratories
North Liberty, Iowa, United States
Rodrigo E. Mendes, PhD (he/him/his)

Director
Element, Iowa City (JMI Laboratories)
North Liberty, IA, United States
CL

Christopher M. Longshaw, PhD

Senior Director, Scientific Affairs EU
Shionogi B.V.
London, England, United Kingdom
MT

Miki Takemura, n/a

Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research
Shionogi & Co., Ltd
Toyonaka, Osaka, Japan
Yoshinori Yamano, PhD (he/him/his)

Chief Scientific Officer for Infectious Diseases
Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan

Disclosure(s):

Boudewijn L. DeJonge, PhD: Shionogi Inc.: Employee

Sean T. Nguyen, PharmD: Shionogi Inc.: Employee

Jason J. Bryowsky, PharmD, MS: Shionogi: Employee

Joshua Maher, PhD: No financial relationships to disclose

Rodrigo E. Mendes, PhD: JMI: RM is an employee of JMI. JMI was contracted by and received financial support from GSK to conduct gepotidac; Paratek Pharmaceuticals: Advisor/Consultant, Grant/Research Support

Christopher M. Longshaw, PhD: Shionogi BV: Employee

Miki Takemura, n/a: Shionogi & Co., Ltd.: Employee

Yoshinori Yamano, PhD: Shionogi & Co., Ltd.: Employee